Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AN2 Therapeutics, Inc. - Common Stock (NQ: ANTX )

1.060 -0.030 (-2.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AN2 Therapeutics, Inc. - Common Stock

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at Jefferies Healthcare Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Participate in Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From AN2 Therapeutics, Inc.
Via GlobeNewswire
AN2 Therapeutics to Present at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via GlobeNewswire
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
From AN2 Therapeutics, Inc.
Via GlobeNewswire
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease
From AN2 Therapeutics, Inc.
Via GlobeNewswire
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
NIAID Agreement to Advance Development of Epetraborole for Acute Systemic Melioidosis 
From AN2 Therapeutics, Inc.
Via GlobeNewswire
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
From AN2 Therapeutics, Inc.
Via Business Wire
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
Via FinancialNewsMedia
Topics Death
Exposures Death
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.